Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853539 | 0.94 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL853540 | 0.94 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL1055082 | 0.94 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL14037432 | 0.94 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL13177349 | 0.94 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL2930907 | 0.90 | USP30 (0.59) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL2930905 | 0.90 | USP30 (0.59) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL22392269 | 0.89 | USP30 (0.58) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL22402113 | 0.89 | USP30 (0.58) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL22392270 | 0.89 | USP30 (0.58) | USP30L3MBTL1ATMALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497383-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120142752-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142752-A1 | HIV PROTEASE INHIBITORS | SERPINB1, PRSS1, SERPINB6 | USP30 2503/4885L3MBTL1 806/4885ATM 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.